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Wstęp. Monitorowanie glikemii stanowi zasadniczy element intensywnej insulinoterapii w cukrzycy typu 1 (T1DM). Cele. 
Celem niniejszej prospektywnej pracy klinicznej było 1) modyfikacja leczenia cukrzycy w grupie dzieci i młodzieży z T1DM 
na podstawie wyników ciągłego monitorowania glikemii (CGM); 2) zastosowanie CGM do oceny tak zmienionego lecze-
nia. Pacjenci i metody. U 61 chorych z T1DM (30 dziewcząt), w średnim wieku 12 lat i 4 miesiące, dwukrotnie – na począt-
ku badania oraz po okresie 3 miesięcy – wykonano ciągłe monitorowanie glikemii oraz oznaczono odsetek hemoglobiny 
glikowanej (HbA1c). Na podstawie wyników pierwszego CGM, u każdego pacjenta wprowadzono zmiany w insulinotera-
pii. Wyniki. Odsetek chorych, u których stwierdzono występowanie epizodów hipoglikemii oraz hiperglikemii, nie uległ 
istotnej zmianie w trakcie trwania badania, i wynosił odpowiednio 93 vs 91% i 100 vs 100%. Po okresie 3 miesięcy zmodyfi-
kowanego leczenia nie zanotowano także istotnych zmian w liczbie epizodów hipoglikemii (1,4±1,0 vs 1,3±0,9 epizodów/
pacjenta/dobę, p>0,05) oraz dobowej dawce insuliny (0,89±0,25 vs 0,87±0,24 U/kg/dobę, p>0,05). Uzyskano natomiast 
istotne statystycznie obniżenie średniej wartości HbA1c (7,7 vs 7,3%, p<0,01) oraz liczby (2,9±1,0 vs 2,3±0,8 epizodów/
pacjenta/dobę, p<0,001) i czasu trwania epizodów hiperglikemii (7,3±3,4 vs 5,7±3,1 godzin/pacjenta/dobę, p<0,01). 
Wnioski. Ciągłe monitorowanie glikemii jest pomocne w obniżeniu odsetka HbA1c, któremu nie towarzyszy wzrost do-
bowej dawki insuliny czy też zwiększone ryzyko wystąpienia hiperglikemii lub hipoglikemii. Należy jednak zaznaczyć, że 
większość dzieci i młodzieży z cukrzycą typu 1 doświadcza patologicznych dobowych wahań glikemii, pomimo poprawy 
kontroli cukrzycy, mierzonej spadkiem odsetka HbA1c.
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Background. Glucose monitoring constitutes an essential part of intensive management of type 1 diabetes mellitus 
(T1DM). Objectives. This prospective, clinical study was aimed to: 1) modify the treatment of T1DM in a group of children 
and adolescents, based on the results provided by the continuous glucose monitoring (CGM); 2) use CGM for the assessment 
of such a modified treatment. Subjects and methods. 61 patients with T1DM (30 girls), at the mean age of 12.4 years were 
studied. CGM and glycohemoglobin (HbA1c) measurement were performed twice: at the study entry and after a 3-month 
period. Based on the results of the first CGM insulin therapy was modified in all the participants. Results. The percentage of 
patients experiencing hypoglycemias and hyperglycemias did not change significantly throughout the study, 93 vs 91%, 
and 100 vs 100%, respectively. After a 3-month period of modified treatment, there was no change in either the number 
of hypoglycemic episodes (1.4±1.0 vs 1.3±0.9 episodes/patient/day, p>0.05) or daily insulin dose (0.89±0.25 vs 0.87±0.24 
U/kg/day, p>0.05). Yet, there was a significant decrease in mean HbA1c (7.7 vs 7.3%, p<0.01) and in the number (2.9±1.0 
vs 2.3±0.8 episodes/patient/day, p<0.001) and duration of hyperglycemic episodes (7.3±3.4 vs 5.7±3.1 hours/patient/day, 
p<0.01). Conclusions. CGM is helpful in improving HbA1c, without increasing insulin dose or the risk of hyperglycemic 
or hypoglycemic episodes. However, majority of children and adolescents with T1DM develop pathological glucose 
excursions in spite of the improvement in glycemic control (shown as a decline in HbA1c).
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Introduction
In the last decades, a constant increase in the annual 
incidence of childhood type 1 diabetes mellitus 
(T1DM) has been observed worldwide [1], especially 
in the youngest age group (below 5 years of life). 
In Finland, where the incidence rate is the highest, 
in last years it exceeded 40 per 100 000, in the age 
group up to 14 years. Our own epidemiological data 
from the Krakow region, South Poland, for the year 
2003 indicate the incidence rate of 13.7 per 100 000, 
which is approximately 3 times higher than it used 
to be in 1989 (4.7/100 000) [2]. In 2006, the United 
Nations together with IDF (International Diabetes 
Federation) passed a resolution recognizing diabetes 
mellitus as a global epidemic, which demands an 
international search for global solution. It was proven 
that late microvascular complications can be prevented 
or delayed by good glycemic control and intensive 
insulin therapy in adolescents and adults with T1DM 
[3, 4]. Other studies demonstrated the same effect 
for children before and during puberty [5, 6]. A tight 
control, however, was associated with an increased 
risk of severe hypoglycemia [7]. Therefore, there is 
a great need for improving glycemic control and safety 
of treatment in children and adolescents with T1DM. 
Rapid acting and long acting insulin analogs, as well 
as pomp therapy seem to facilitate the achievement 
of these goals [8, 9]. Nevertheless, progress should 
be made not only in the development of new insulin 
preparations or methods of insulin administration, 
but also in self-monitoring of blood glucose, which 
constitutes an essential part of intensive insulin 
therapy. Continuous glucose monitoring (CGM), 
which provides a new insight into daily glucose profiles 
for a diabetic team and a patient, might be an option. 
The purpose of this study was 1) to use the results 
provided by CGM for modification of the treatment in 
a group of children and adolescents with T1DM, and 
2) to assess the implementation of that alteration by 
means of CGM. 
Materials and methods
Children and adolescents with T1DM diagnosed 
according to the WHO criteria [10] and followed-
up in the Department of Pediatric and Adolescent 
Endocrinology, Krakow, Poland, were invited to 
participate in this prospective clinical study if they 
were at the age between 2 and 18 years, were treated 
with insulin for at least 9 months and had no other 
chronic diseases, except from primary hypothyroidism 
in euthyroid state. Sixty-one consecutive patients, 
who had first given their written, informed and 
witnessed consent, were included into the study. All 
clinical procedures were completed between February 
2004 and September 2005. The characteristics of the 
studied group are given in table 1. 
Glycohemoglobin and continuous glucose 
monitoring
Glycohemoglobin (HbA1c) was measured in 
capillary blood, in one laboratory, using the reference 
method of high performance liquid chromatography 
which had been certified by the NGSP (National 
Glycohemoglobin Standardization Program). The 
normal range fell within 4.2–6.3%. Continuous 
glucose monitoring was performed using the system 
produced by MINIMED, USA, which was described 
in details elsewhere [11]. In general, the CGM system 
measured continuously, for 3–4 subsequent days, 
glucose concentration in the interstitial fluid of the 
subcutaneous fat tissue. Records of the mean glucose 
values, within the range of 40–400 mg/dl, were made 
every 5 minutes, which gave 288 glycemic results 
per 24 hours. When the monitoring was finished, the 
stored data were retrospectively analyzed by a special 
software. Hypoglycemia was defined as blood glucose 
≤ 60 mg/dl (3.3 mmol/l) and hyperglycemia as values 
≥ 180 mg/dl (10 mmol/l). For both hyperglycemias 
and hypoglycemias, the number of episodes per 
patient per day, as well as the duration in hours per 
patient per day was calculated. 
Research design
At the study entry, all the 61 patients underwent 
the first continuous glucose monitoring (CGM-1) in 
an ambulatory setting. HbA1c was also measured in 
all the subjects. The results of CGM-1 were analyzed 
by the same physician and discussed with the patients 
and their families. If appropriate, changes in diabetes 
therapy were introduced. After a 3-month period of 
such modified treatment, HbA1c was checked again 
in all the subjects and the second ambulatory CGM 
(CGM-2) was performed in 56 patients (92% of the 
studied group, 29 girls and 27 boys). Five patients, who 
did not undergo the second CGM because of family 
problems, did not differ in age, diabetes duration or 
HbA1c value from those patients who completed the 
repeated CGM. 
The study was reviewed and approved by the local 
Ethical Board of Collegium Medicum, Jagiellonian 
University, Krakow (number KBET/86/B/2004). 
The statistical analysis was carried out using the 
STATISTICA 7.0 PL software. The data are given 
as mean ± SD, unless indicated otherwise. For the 
comparison of two sets of data, the Student’s t test or 
U Mann-Whitney test was used. The changes in time 
were analyzed using repeated measures of analysis of 
variance, the Friedman test or Kruskal-Wallis test. The 
regression analysis with correlation coefficient was 
employed. The statistical significance was defined as 
p<0.05.
Results
The mean HbA1c in the entire studied group was 
7.7±1.3% at the study entry. Twenty-three patients had 
HbA1c less than 7.0%, 20 – between 7.0 and 8.0%, and 
in 18 subjects, HbA1c exceeded 8.0%. CGM was well 
tolerated, and all the participants completed CGM-1, 
which lasted an average of 4.2 days per patient. There 
were no episodes of acute metabolic decompensations. 
The mean glycemia calculated from the results of 
CGM-1 was 154±24 mg/dl (range, 103–229 mg/dl). 
A positive correlation was found between the mean 
HbA1c and mean glycemia (r=0.44, p<0.001). It 
suggests that CGM performed in a few-day period 
gives comparable information about the mean glycemic 
value as HbA1c level, measured every 3 months. 
CGM-1 revealed 324 episodes of hypoglycemia in 
57 patients (93% of the studied group). On average, 
one patient experienced 1.3±1.0 hypoglycemic 
episodes per day with the mean duration of 1.0±1.2 
hour. Boys had significantly more low blood glucose 
values than girls (1.5 vs 1.1 episodes/patient/day, 
p=0.047), similarly as prepubertal children compared 
to patients in puberty (2.0 vs 1.2 episodes/patient/
day, p=0.015). The results of CGM-1 proved the 
presence of hyperglycemic episodes in all the 61 
studied patients. Altogether, as many as 747 episodes 
of high blood glucose were registered. One patient 
experienced an average of 2.9 ± 1.0 episodes/
patient/day, with the mean duration of 7.3 ± 3.5 
hours/patient/day. Patients treated with rapid acting 
analogs had fewer hyperglycemic episodes than 
those treated with regular human insulin (2.6 vs 3.4 
episodes/patient/day, p=0.02). Similarly, subjects on 
pump therapy had less hyperglycemias than those on 
multiple daily injections (2.5 vs 3.2 episodes/patient/
day, p<0.01). There was a tendency for the highest 
number of hyperglycemic episodes in children with the 
shortest diabetes duration (less than 3 years) and in 
prepubertal patients (3.5 episodes/patient/day), but 
the differences did not reach statistical significance. 
Based on the detailed information provided by 
CGM-1 about glycemic daily profiles, and the result 
of HbA1c, appropriate changes were introduced in 
the therapeutic regimen and self-control of diabetes in 
all the 61 patients. The most common modifications 
included:
1. An introduction or modification of correction 
algorithm (in 55 cases). 
2. The observance of an appropriate time interval 
between an insulin injection and a meal. 
Table 1.  
Characteristics of the studied group at the study entry
Number n=61
Gender (male : female) 31 : 30
Age [yrs] (mean, range, median) 12.3 (5–17.5, 13)
Age at the T1DM diagnosis [yrs] (mean, range, median) 7 (1.7–15.6, 6.4)
Diabetes duration [yrs] (mean, range, median) 5.3 (0.7–14, 5.3)
BMI <90th; 90th–97th; >97th percentile 55 : 4 : 2
Tanner scale I˚ : II-IV˚ : V˚ 10 : 37 : 14
MDI : CSII 41 : 20
Prandial insulin in patients on MDI, rapid acting analog : regular insulin 14 : 27
Basal insulin in patients on MDI, long acting analog : NPH insulin 8 : 33
Insulin preparation used in CSII, rapid acting analog : regular insulin 20 : 0
Daily insulin dose [U/kg/day] (mean ± SD) 0.89 ± 0.25
HbA1c < 7.0% : 7.0–8.0% : > 8.0% 23 : 20 : 18
T1DM – type 1 diabetes mellitus, BMI - body mass index (percentiles for gender and age), MDI – multiple daily injections, CSII – conti-
nuous subcutaneous insulin infusion, NPH – neutral protamine Hagedorn, SD – standard deviation, HbA1c – glycohemoglobin A1c
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especially if pre-prandial hyperglycemia was 
present (in 40 cases).
3. A correction of an insulin/carbohydrate 
exchange ratio in pump therapy or an insulin 
dose per meal in pen therapy (in 52 cases).
4. Changes in diet: appropriate meal timetable and 
content, accurate meal weighing, modifications 
of regimen for high fat/protein meals or high 
glycemic index foods (in 46 cases).
5. An alteration in the individual approach to 
exercise (in 31 cases).
6. A change of basal insulin dosage (in 28 cases) or 
in the time of its injection (in 6 cases).
7. A change of insulin injection site, in case of 
lipohypertrophy (in 13 cases). 
8. Usage of dual boluses in pump therapy (in 13 
cases).
9. A personal plan for hypoglycemia prevention 
and management (in 13 cases).
10. An increase in the number of daily insulin 
injections in patients on MDI (in 12 cases).
11. An absolute need for routine change of an 
infusion set every 3 days in pump therapy (in 8 
cases).
12. An absolute need for self-monitoring of blood 
glucose before every single injection of rapid 
acting analog (in 4 cases).
13. A change of prandial insulin (from regular to 
rapid acting analog) or basal insulin preparation 
(from NPH to long acting analog) (in 8 cases).
14. An absolute need for urine ketone test in case of 
prolonged hyperglycemia in patients on CSII (in 
3 cases).
After a 3-month period of such a modified therapy, 
the mean HbA1c value in the entire studied group 
decreased significantly (7.3% vs 7.7%, p<0.01). 
Beneficial changes in HbA1c were seen in 43 patients 
(70% of the subjects). Four patients had exactly the 
same HbA1c value at the end of the study: 6.1%, 6.4%, 
6.6% and 8.4%, respectively. In 14 patients, HbA1c 
increased during the study. To sum up: at the end of 
the study period, 33 patients had HbA1c < 7.0%, 17 
between 7.0 and 8.0%, and 11 subjects had HbA1c> 
8.0%. 
The mean duration of CGM-2 was 4.4 days. A 
comparison of the mean glycemia calculated from 
CGM-1 and CGM-2 values showed a significant 
decrease at the end of the study (140±23 vs 154±24 
mg/dl, p<0.01), in accordance with the HbA1c decline. 
The results of CGM-2 revealed 303 hypoglycemic 
episodes in 51 out of 56 monitored subjects (91%). 
One patient experienced an average of 1.3±0.9 
episodes of low blood glucose per day, which did not 
differ significantly from the CGM-1 results (1.4±1.0 
episodes/patient/day, p=0.46). The duration of 
hypoglycemic episodes was not significantly different 
either (1.1±1.2 vs 1.6±1.7 hours/patient/day, p=0.11) 
(tab. 2). As to hyperglycemic episodes, they were still 
present in all the 56 monitored patients at the end 
of the study. However, their number and duration 
decreased significantly after a 3-month period of 
modified treatment (2.3±0.8 vs 2.9±1.0 episodes/
patient/day, p<0.001 and 5.7±3.1 vs 7.3±3.6 hours/
patient/day, p<0.01) (tab. 2). An improvement in the 
mean HbA1c value and a decrease in the number of 
hyperglycemias was achieved without an increase in 
daily insulin dose, which did not change throughout 
the study period either in the entire group (0.87±0.24 
U/kg/day vs 0.89±0.25 U/kg/day, p=0.43) or among 
patients whose HbA1c had declined (0.88 vs 0.88 U/
kg/day, p=0.96). These results, together with the lack 
of correlation between the mean daily insulin dose and 
mean HbA1c in the studied group, suggest that the 
total insulin dose is not the only factor influencing the 
results of glycemic control. 
Discussion
The objective of the present study was to employ 
continuous glucose monitoring 1) to alter the diabetes 
regimen in a group of children and adolescents 
with T1DM, and 2) to assess the results of such 
a modified treatment. To our best knowledge, this is 
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Table 2.  
Hyperglycemic and hypoglycemic episodes (means ±SD) seen in continuous glucose monitoring at 
the beginning of the study (CGM-1) and after a 3-month period of modified treatment (CGM-2) in 56 
patients
Hyperglycemia Hypoglycemia
CGM-1 CGM-2 CGM-1 CGM-2
Number of episodes/patient/day 2.9±1.0*** (1.2–5.3) 2.3±0.8*** (0.5–3.8) 1.4±1.0 (0.2–4.5) 1.3±0.9 (0,2–3.6)
Duration of episodes/patient/day 
[hours] 7.3±3.4** (1.0–17.0) 5.7±3.1** (0.3–13.2) 1.1±1.2 (0–6.3) 1.6±1.7 (0–8.1)
** p<0.01, *** p<0.001
the first attempt to use the repeated CGM for a critical 
evaluation of the changes in glycemic control, as the 
other studies aiming at improving diabetes control 
on the basis of CGM used repeated measurements of 
HbA1c as the only criterion. 
The results of CGM-1 confirmed the presence 
of hypoglycemic episodes in the majority (93%) of 
children and adolescents with T1DM, who were on 
insulin therapy. Therefore, CGM turned out to be 
a valuable tool in detecting hypoglycemic episodes; 
of many of them the patients were completely 
unaware. Using the same method, other authors 
observed episodes of low blood glucose in 83% 
and 100% of the studied patients [12, 13]. In the 
present study, one patient experienced an average of 
1 hypoglycemic episode per day. Similar results were 
obtained by other authors: 1.1 episodes/patient/day 
in preschool children [14], and 1.2 episodes/patient/
day in patients from 5 to 19 years of age [13]. Based 
on our CGM results, it seems that prepubertal 
children, especially boys, constitute a group of 
diabetic patients who are particularly susceptible 
to hypoglycemia. As to high blood glucose levels, 
they were present in all the patients, with the mean 
frequency of 3 episodes per patient per day. Other 
studies yielded similar results – 3 episodes/patient/
day in preschool children with the mean HbA1c 
of 8.1% [14] and 2 episodes/patient/day (defined 
differently – as glycemia higher than 270 mg/dl) in 
older patients with the mean HbA1c of 8.0% [13]. 
Based on our CGM results, the MDI regimen and 
the use of regular insulin preparations seem to carry 
a higher risk for hyperglycemia, comparing with 
CSII and rapid acting analogs. 
Our observations, in agreement with results 
published by other authors [15, 16], suggest that 
information about daily glycemic profiles provided 
by CGM allows the diabetic team for introducing 
more accurate changes in current diabetes regimen 
as compared to traditional self-monitoring of blood 
glucose (SMBG). In the present study, the treatment 
was altered in all the patients who had undergone 
CGM. In the majority of patients, the recommendations 
concerned principles of self-control, SMBG, diet 
and basic rules of insulin therapy, whereas insulin 
preparations were changed only in 8 cases. Similar 
recommendations for altering the diabetes regimen 
were introduced by Kaufman and al. in 47 children 
at the mean age of 12 years, treated with CSII or 
MDI [12], and by Ludvigsson and Hanas [13]. After 
3 months of such a modified treatment, glycemic 
control, assessed by the mean HbA1c value, improved 
significantly in the mentioned studied groups, by 0.2% 
and 0.4%, respectively. Results of other observational 
studies aiming at improving diabetes control using 
CGM were similar [12, 17]. Further evidence for 
efficacy of CGM in improving HbA1c came from 
randomized clinical trials with a control group [13, 
18]. The authors proved that HbA1c decreased 
significantly only in patients who used the results 
of CGM to alter their day-to-day diabetes regimen, 
but not in those who were blinded for CGM results 
and used only SMBG. However, in spite of the 
significant improvement in the mean HbA1c achieved 
in our study, the second CGM performed in order to 
compare the number and duration of hypoglycemic 
and hyperglycemic episodes before and after therapy 
changes revealed glycemic excursions in the majority 
of the patients. A significant decrease in both the 
number and duration of hyperglycemias, which goes 
together with a decline in the mean glycemia and mean 
HbA1c value, is encouraging in terms of prevention of 
late diabetic complications. Lack of the increase in the 
number and duration of hypoglycemic episodes is also 
very positive, as it may suggest that intensive insulin 
therapy – particularly CSII with rapid acting insulin 
analogs - allows for improving glycemic control without 
our worrying about an increase in hypoglycemia rate. 
It is also worth mentioning that the total daily insulin 
dose did not change throughout the study, implying 
that the insulin dose itself is not the crucial factor of 
good glycemic control. The insulin regimen, type for 
insulin preparations together with careful self-control 
seem to be more important. 
Conclusions
Given our results and those of the previous studies, 
we assume that CGM provides a detailed insight 
into daily glycemic excursions and trends in children 
and adolescents with type 1 diabetes mellitus. It 
allows the diabetes team for making more accurate 
therapeutic decisions. The usage of CGM leads to an 
improvement in glycemic control assessed by HbA1c, 
without increasing the risk of severe hypoglycemia. 
Therefore, continuous glucose monitoring should 
be used together with HbA1c value to evaluate the 
results of diabetes therapy. However, the long-term 
benefits of its use remain to be determined in longer 
clinical trials.
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